0001209191-21-010517.txt : 20210212 0001209191-21-010517.hdr.sgml : 20210212 20210212212843 ACCESSION NUMBER: 0001209191-21-010517 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210210 FILED AS OF DATE: 20210212 DATE AS OF CHANGE: 20210212 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: LOUMEAU ERIC J CENTRAL INDEX KEY: 0001239648 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37985 FILM NUMBER: 21631557 MAIL ADDRESS: STREET 1: C/O HOLLIS-EDEN PHARMACEUTICALS STREET 2: 4435 EASTGATE MALL STE.400 CITY: SAN DIEGO STATE: CA ZIP: 92121 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: ANAPTYSBIO, INC CENTRAL INDEX KEY: 0001370053 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 203828755 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-362-6295 MAIL ADDRESS: STREET 1: 10421 PACIFIC CENTER COURT, SUITE 200 CITY: SAN DIEGO STATE: CA ZIP: 92121 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYSBIO INC DATE OF NAME CHANGE: 20080828 FORMER COMPANY: FORMER CONFORMED NAME: ANAPTYS BIOSCIENCES INC DATE OF NAME CHANGE: 20060724 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2021-02-10 0 0001370053 ANAPTYSBIO, INC ANAB 0001239648 LOUMEAU ERIC J C/O ANAPTYSBIO, INC. 10421 PACIFIC CENTER COURT, SUITE 200 SAN DIEGO CA 92121 0 1 0 0 COO, General Counsel Common Stock 2021-02-12 4 M 0 10000 14.02 A 10000 D Common Stock 2021-02-12 4 S 0 10000 35.00 D 0 D Stock Option (right to buy) 29.70 2021-02-10 4 A 0 45000 0.00 A 2031-02-09 Common Stock 45000 45000 D Stock Option (right to buy) 14.02 2021-02-12 4 M 0 10000 0.00 D 2029-12-08 Common Stock 10000 88000 D The transaction reported on this Form 4 were effected pursuant to a Rule 105b-1 trading plan adopted by the reporting person. The stock option vests and becomes exercisable as to 25% of the shares subject to the option on February 10, 2022, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. The stock option vested as to 25% of the shares subject to the option on December 6, 2020, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date. In addition to the remaining option to purchase 88,000 shares of common stock as set forth in Table II, the Reporting Person also holds additional options to purchase up to an aggregate of 147,500 shares of common stock, which options vest according to their terms. /s/ Eric Loumeau 2021-02-12